Cancer drug combo trial ends early after only 9 patients
NCT ID NCT05036681
First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 36 times
Summary
This study tested a combination of two drugs, futibatinib and pembrolizumab, in people with a hard-to-treat type of advanced endometrial cancer called microsatellite stable (MSS). The goal was to see if the combo could shrink tumors or slow the cancer. The trial was stopped early after enrolling only 9 participants, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.